NEW BRUNSWICK, N.J. – Christopher J. Molloy, who has successfully managed the complex process of Rutgers University’s impending integration with most of the University of Medicine and Dentistry of New Jersey, will serve as interim chancellor of the new Rutgers Biomedical and Health Sciences beginning July 1.
Molloy is expected to hold the position until the university completes its search for a permanent chancellor, Rutgers President Robert L. Barchi announced today.
Molloy, a molecular and cellular pharmacologist, has served as interim provost for biomedical and health sciences at Rutgers since October 2011. He joined Rutgers as dean of the Ernest Mario School of Pharmacy in 2007.“Chris Molloy has done an outstanding job managing one of the most complex higher education restructuring initiatives in history,” President Barchi said. “In the days immediately following integration, Chris is clearly the individual most qualified at Rutgers to oversee this historic transition as we complete our search for a permanent chancellor for Rutgers Biomedical and Health Sciences.”
Under the New Jersey Medical and Health Sciences Education Restructuring Act, which takes full effect July 1, most of the schools and institutes that make up the University of Medicine and Dentistry of New Jersey will become part of Rutgers Biomedical and Health Sciences, which also will include the Ernest Mario School of Pharmacy; the Rutgers College of Nursing; and the Institute for Health, Health Care Policy and Aging Research. This restructuring will elevate Rutgers to the ranks of the nation’s finest comprehensive research universities.
Molloy received a Bachelor of Science degree in pharmacy at Rutgers in 1977. He went on to earn his Ph.D. from the joint Rutgers-UMDNJ Graduate Program in Toxicology. Subsequently, he was a post-doctoral fellow at the National Cancer Institute, National Institutes of Health.
Before returning to Rutgers in 2007, Molloy worked for Johnson and Johnson Pharmaceutical Research and Development L.L.C., where he served as a senior research fellow and team leader in the East Coast Research and Early Development unit. Molloy previously held senior positions with 3-Dimensional Pharmaceuticals Inc. and the Bristol-Myers Squibb Pharmaceutical Research Institute.
Established in 1766, Rutgers, The State University of New Jersey, is America’s eighth oldest institution of higher learning and one of the nation’s premier public research universities. Serving nearly 60,000 students on campuses, centers, institutes and other locations throughout the state, Rutgers is one of only two New Jersey institutions represented in the prestigious Association of American Universities.